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Open Access
Case Report

Euglycemic Diabetic Ketoacidosis in a 27 year-old female
patient with type-1-Diabetes treated with sodium-glucose
cotransporter-2 (SGLT2) inhibitor Canagliflozin
Nimrah Bader1, Lubna Mirza2
ABSTRACT
We are reporting a timely case of atypical euglycemic diabetic ketoacidosis in a type 1 diabetic patient
treated with sodium-glucose cotransporter-2 (SGLT-2) inhibitor canagliflozin. The clinical history, physical
examination findings and laboratory values are described. Other causes of acidosis such as salicylate toxicity
or alcohol intoxication were excluded. Ketoacidosis resolved after increasing dextrose and insulin doses
supporting the hypothesis that SGLT-2 inhibitors may lead to hypoinsulinemia. Euglycemic ketoacidosis did
not recur in our patient after discontinuing canagliflozin. We recommend reserving SGLT2 inhibitor therapy
to type 2 diabetics, discontinuing medication and treating patients presenting with ketoacidosis due to
SGLT-2 inhibitors with higher concentrations of dextrose with appropriate doses of insulin to help resolve
acidosis.
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INTRODUCTION
Sodium glucose co-transporter 2 (SGLT2)
inhibitors are one of the newest anti-diabetic
drugs that improve glycemic control by increasing
urinary excretion of glucose. SGLT2 inhibitors are
indicated for type 2 diabetics as adjunct to diet and
exercise. They improve weight and blood pressure
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as well with glucosuria. Since the launch of the
medication, several cases of diabetes ketoacidosis
(DKA) have emerged. We present a case of type 1
diabetic patient treated with SGLT2 inhibitor who
was admitted to the hospital with DKA. Literature
review shows since the approval of drug class in
2013, these drugs increase risk for DKA. The risk
is higher in autoimmune diabetes. In May 2015, the
Food and Drug Administration issued a warning
that SGLT2 inhibitors may lead to ketoacidosis.
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A literature search was conducted on the ClinAlert database for adverse reactions and PubMed
using keywords ‘SGLT2’; ‘canagliflozin’ and
‘ketoacidosis’. Results revealed two cases where
ketoacidosis was seen in Type 2 diabetics after
they were started on an SGLT-2 Inhibtor.1 Possible
mechanism behind the euglycemic ketoacidosis
was also identified.2 We hope that writing this
case report may highlight this potential side
effect in Type 1 Diabetics as well. Our case report

Euglycemic Diabetic Ketoacidosis

features a young woman with type 1 diabetes who
developed ketoacidosis eight months after starting
canagliflozin.
CASE REPORT
A 27-year-old Caucasian woman with type
1 diabetes was admitted to the hospital with
ketoacidosis. She was first diagnosed with type
1-diabetes 15 years ago. She was using an insulin
pump since age 18. Past medical history was
significant for primary hypothyroidism and
depression. She was started on sodium-glucose
cotransporter-2 (SGLT2) inhibitor canaglifozin 8
months earlier by Endocrinologist. After starting
treatment with canaglifozin her insulin requirement
went down. She lost about four pounds of weight
and her hemoglobin A1C improved slightly from
8.6% to 8.4% six months after starting canagliflozin.
The day before presentation she worked the night
shift, slept all day the next day and woke up at 5:00
p.m. She felt nauseated with heavy breathing and
muscular pains. She also noticed spots in her vision.
Her blood sugar was normal at 114 mg/dl. She had
eaten a grilled cheese sandwich before going to sleep
along with two beers. No history of aspirin use. She
worked as a nurse and drank alcohol only three
to four times a year. There was a positive family
history for autoimmune hypothyroidism in her
mother. She had no known drug allergies and her
home medications included Dexvenlafaxine 50mg
orally for depression at bedtime and Levothyroxine
150mcg orally once daily for hypothyroidism.
She was treated with intravenous 5% Dextrose
with half normal saline and insulin in the
emergency room before being transferred to the
Intensive care unit, but the anion gap didn’t close
despite continued intravenous 5% Dextrose and
insulin administration 24 hours later. At this
point Endocrinology services were consulted.
She was found to be in overall stable condition.
Her Temperature was 36.8 degrees centigrade,
pulse was 72 beats per minute, respiratory rate was
16, Blood pressure 131/73 and pulse ox was 98%
on room air. She was awake and in no distress.
Physical examination was unremarkable.
Laboratories Studies: Sodium 134, potassium 3.9,
chloride 110, CO2 12, glucose 132mg/dl, calcium
8.2mg/dl, TSH 0.92 with free T4 of 0.99. Anion gap
was 16, which was improved from 20 on admission,
but had not changed in the last 24 hours. Beta
hydroxybutyrate were positive. Corticotrophin
stimulation test ruled out adrenal insufficiency and
serum salicylate levels were not high. Toxicology

screen was negative for alcohol or other commonly
abused illicit drugs.
Canagliflozin use was suspected as a likely reason
for development of resistant and unusual diabetes
ketoacidosis episode in this patient. High fat meal
and use of alcohol were linked to triggering of this
episode. We recommended increasing dextrose
infusion to 10% to help expedite removal of beta
hydroxybutyrate. By next morning her anion gap
closed, she felt better and she was discharged home.
She stayed off of SGLT2 inhibitor and didn’t have
any further episodes of euglycemic ketoacidosis.
DISCUSSION
Sodium glucose transporters -2 (SGLT-2) inhibitors have recently emerged as a novel way to treat
diabetes and improve glycemic control. Canagliflozin was the first drug in this class approved by
the Food and Drug Administration (FDA) in March
2013.3 SGLTs are a family of sodium glucose cotransporters. SGLT-2 is present almost exclusively
in brush border of epithelial cells in the proximal
tubule of the kidney. It is responsible for reabsorbing around 90% of filtered glucose. SGLT-2 inhibitors exploit this phenomenon by antagonizing the
transporter.4 This leads to increased glucose excretion, improving glycemic control.5 While the use of
SGLT-2 inhibitors in Type 2 diabetics has been extensively studied both as a single agent and in combination in terms of efficacy and safety,6-10 several
independent smaller studies have shown benefit in
Type 1 Diabetics as well.11,12 Our clinical experience
in treating a patient with Type 1 diabetes resulted
in an unexpected side effect – euglycemic diabetic
ketoacidosis.
Diabetic ketoacidosis (DKA) is a life threatening
condition characterized by uncontrolled hyperglycemia, increased levels of ketones and metabolic acidosis. DKA is much less commonly seen in type 2
diabetes as compared to type 1 diabetics. The mechanism behind DKA is hormonal derangements
between insulin and other counter regulatory hormones like glucagon, cortisol, growth hormone and
catecholamines.13 In the case of our type 1 diabetic
patient, glucose levels were normal suggesting this
was an atypical case of DKA.
SGLT-2 inhibitors help improve glycemic control
in diabetic patients by preventing renal glucose
re-absorption as mentioned earlier in the paper.
However, treatment in subjects with type 2 diabetes
increases both plasma glucagon and endogenous
glucose production, which may be the cause behind
the normoglycemia during atypical DKA. Biological
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research on this factor has mostly focused on islet
cells of Type 2 diabetics.
The exact mechanisms are unknown at present
time. In a recently published study in Nature, it is
demonstrated that SGLT2 is expressed in glucagonsecreting alpha cells of the pancreatic islets.14 The
investigators further found that expression of
SLC5A2 (which encodes SGLT2) was lower and
glucagon (GCG) gene expression was higher in islets
from type 2 diabetic individuals and in normal islets
exposed to chronic hyperglycemia than in islets
from non-diabetics. In addition SGLT-2 inhibitor
treatment in human islets triggered glucagon
secretion through KATP channel activation.
The investigators also found that dapagliflozin
treatment further promotes glucagon secretion and
hepatic gluconeogenesis in healthy mice, thereby
limiting the decrease of plasma glucose induced by
fasting. This may be a possible mechanism behind
the masking of hyperglycemia in this patient.
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CONCLUSIONS
SGLT2 inhibitors are an exciting new drug class
that is safe and efficient in most type 2 diabetes
patients. SGLT2 inhibitors can cause DKA in both
type 1 and type 2 diabetes. Patients and healthcare
providers need to be educated on signs and
symptoms of DKA associated with SGLT2 inhibitors
for reducing patient morbidity and mortality.
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